Key facts
- This page summarizes Fayaz Khazi's Form 4 filing for PRECISION BIOSCIENCES INC (DTIL).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2021, 18:39.
Fayaz Khazi - 07 Jun 2021 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)
- Reporting relationship
- CEO of Elo Life Systems
- Issuer ticker
- DTIL
- Reported as of
- 07 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Dario Scimeca, Attorney-in-Fact for Fayaz Khazi
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Fayaz Khazi filed Form 4 for PRECISION BIOSCIENCES INC (DTIL) on 09 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DTIL
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +41,240
- Change %
- Price
- $0.000000
- Shares after
- 41,240
- Date
- 07 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,240
- Exercise price
- $11.34
- Footnotes
- F1
DTIL
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +23,999
- Change %
- Price
- $0.000000
- Shares after
- 23,999
- Date
- 07 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,999
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date.
Footnote F2
The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock.
Footnote F3
The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.